UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models

Nature communications, 2016-07, Vol.7 (1), p.12258-12258, Article 12258

2016

Volltextzugriff (PDF)

Neurexins and neuroligins: synapses look out of the nervous system

Cellular and molecular life sciences : CMLS, 2011-08, Vol.68 (16), p.2655-2666

2011

Volltextzugriff (PDF)

Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways

Molecular cancer, 2009-12, Vol.8 (1), p.118-118

2009

Volltextzugriff (PDF)

Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia

Proceedings of the National Academy of Sciences - PNAS, 2012-02, Vol.109 (6), p.1836-1837

2012

Volltextzugriff (PDF)

Patient‐reported outcomes provide prognostic information for survival in patients with diffuse large B‐cell lymphoma: Analysis of 1239 patients from the GOYA study

Cancer medicine (Malden, MA), 2022-09, Vol.11 (17), p.3312-3322

2022

Volltextzugriff (PDF)

P1223: IMAGING MASS CYTOMETRY REVEALS A HIGHLY HETEROGENOUS CELL MAKEUP AND SPATIAL CONTEXT OF THE FOLLICULAR LYMPHOMA TUMOR MICROENVIRONMENT

HemaSphere, 2023-08, Vol.7 (S3), p.e7107091-n/a

2023

Volltextzugriff (PDF)

synaptic proteins neurexins and neuroligins are widely expressed in the vascular system and contribute to its functions

Proceedings of the National Academy of Sciences - PNAS, 2009-12, Vol.106 (49), p.20782-20787

2009

Volltextzugriff (PDF)

Memo has a novel role in S1P signaling and is [corrected] crucial for vascular development

PloS one, 2014-04, Vol.9 (4), p.e94114-e94114

2014

Volltextzugriff (PDF)

P1129: GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B‐CELL LYMPHOMA (LBCL): EXTENDED FOLLOW‐UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY

HemaSphere, 2023-08, Vol.7 (S3), p.e458981a-n/a

2023

Volltextzugriff (PDF)

Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy?

Cellular and molecular life sciences : CMLS, 2013-11, Vol.70 (21), p.4131-4140

2013

Volltextzugriff (PDF)

Cancer: Staying together on the road to metastasis

Nature (London), 2014-10, Vol.514 (7522), p.309-310

2014

Volltextzugriff (PDF)

Neurexins and neuroligins: synapses look out of the nervous system

Cellular and molecular life sciences : CMLS, 2011-08, Vol.68 (16), p.2655-2666

2011

Volltextzugriff (PDF)

Imaging Mass Cytometry Reveals a Highly Heterogenous Cell Makeup of the Follicular Lymphoma Tumour Microenvironment

Blood, 2023-11, Vol.142 (Supplement 1), p.4381-4381

2023

Volltextzugriff (PDF)

GLOBRYTE: A Phase III, Open-Label, Multicenter, Randomized Trial Evaluating Glofitamab Monotherapy in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Blood, 2023-11, Vol.142 (Supplement 1), p.3052-3052

2023

Volltextzugriff (PDF)

Identification of High-Risk Population in First-Line Follicular Lymphoma at Screening with a Next Generation Sequencing (NGS) Assay Using Plasma Circulating Tumor DNA (ctDNA): Initial Data from Gallium

Blood, 2023-11, Vol.142 (Supplement 1), p.1629-1629

2023

Volltextzugriff (PDF)

Analysis of Immune Pharmacodynamic and Baseline Biomarkers in Patients with Relapsed or Refractory Follicular Lymphoma Treated with Mosunetuzumab in Combination with Lenalidomide

Blood, 2022-11, Vol.140 (Supplement 1), p.3555-3556

2022

Volltextzugriff (PDF)

Molecular Mechanisms Underlying Response and Resistance to Glofitamab

Blood, 2023-11, Vol.142 (Supplement 1), p.1619-1619

2023

Volltextzugriff (PDF)

Automated Baseline Fluorodeoxyglucose-Positron Emission Tomography Imaging and High BCL2 Expression Provide Orthogonal Prognostic Value in Predicting High-Risk De Novo Diffuse Large B-Cell Lymphoma Patients

Blood, 2020-11, Vol.136 (Supplement 1), p.8-9

2020

Volltextzugriff (PDF)

Transcriptional regulation of tenascin‐W by TGF‐beta signaling in the bone metastatic niche of breast cancer cells

International journal of cancer, 2015-10, Vol.137 (8), p.1842-1854

2015

Volltextzugriff (PDF)

MCL-339 GLOBRYTE: A Phase III, Open-label Multicenter, Randomized Trial Evaluating Glofitamab Monotherapy in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S515-S515

2024

Volltextzugriff (PDF)

GLOBRYTE: A Phase III, Open-label, Multicenter, Randomized Trial Evaluating Glofitamab Monotherapy in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S227-S227

2024

Volltextzugriff (PDF)

CELESTIMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab plus lenalidomide versus rituximab plus lenalidomide in patients with relapsed or refractory follicular lymphoma who have received ≥ 1 line of systemic therapy

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS7588-TPS7588

2022

Volltextzugriff (PDF)

An EZH2 Gene Expression Signature Is Predictive of Differential Efficacy of Chemotherapy Irrespective of EZH2 Mutation Status in Patients with Follicular Lymphoma Treated within the Gallium Trial

Blood, 2021-11, Vol.138 (Supplement 1), p.39-39

2021

Volltextzugriff (PDF)

1 – 25 von 47

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(44)
Mit Volltextzugriff
(44)

Publikationsform

Artikel
(45)
Buchkapitel
(2)

Sprache

Englisch
(47)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models

Neurexins and neuroligins: synapses look out of the nervous system

Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways

Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia

Patient‐reported outcomes provide prognostic information for survival in patients with diffuse large B‐cell lymphoma: Analysis of 1239 patients from the GOYA study

P1223: IMAGING MASS CYTOMETRY REVEALS A HIGHLY HETEROGENOUS CELL MAKEUP AND SPATIAL CONTEXT OF THE FOLLICULAR LYMPHOMA TUMOR MICROENVIRONMENT

synaptic proteins neurexins and neuroligins are widely expressed in the vascular system and contribute to its functions

Memo has a novel role in S1P signaling and is [corrected] crucial for vascular development

P1129: GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B‐CELL LYMPHOMA (LBCL): EXTENDED FOLLOW‐UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY

Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy?

Cancer: Staying together on the road to metastasis

Neurexins and neuroligins: synapses look out of the nervous system

Imaging Mass Cytometry Reveals a Highly Heterogenous Cell Makeup of the Follicular Lymphoma Tumour Microenvironment

GLOBRYTE: A Phase III, Open-Label, Multicenter, Randomized Trial Evaluating Glofitamab Monotherapy in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Identification of High-Risk Population in First-Line Follicular Lymphoma at Screening with a Next Generation Sequencing (NGS) Assay Using Plasma Circulating Tumor DNA (ctDNA): Initial Data from Gallium

Analysis of Immune Pharmacodynamic and Baseline Biomarkers in Patients with Relapsed or Refractory Follicular Lymphoma Treated with Mosunetuzumab in Combination with Lenalidomide

Molecular Mechanisms Underlying Response and Resistance to Glofitamab

Automated Baseline Fluorodeoxyglucose-Positron Emission Tomography Imaging and High BCL2 Expression Provide Orthogonal Prognostic Value in Predicting High-Risk De Novo Diffuse Large B-Cell Lymphoma Patients

Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study

Transcriptional regulation of tenascin‐W by TGF‐beta signaling in the bone metastatic niche of breast cancer cells

MCL-339 GLOBRYTE: A Phase III, Open-label Multicenter, Randomized Trial Evaluating Glofitamab Monotherapy in Patients with Relapsed or Refractory Mantle Cell Lymphoma

GLOBRYTE: A Phase III, Open-label, Multicenter, Randomized Trial Evaluating Glofitamab Monotherapy in Patients with Relapsed or Refractory Mantle Cell Lymphoma

CELESTIMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab plus lenalidomide versus rituximab plus lenalidomide in patients with relapsed or refractory follicular lymphoma who have received ≥ 1 line of systemic therapy

Glofitamab Plus Polatuzumab Vedotin Continues to Demonstrate Frequent and Durable Responses and Has a Manageable Safety Profile in Patients with ≥2L Relapsed/Refractory DLBCL, Including HGBCL, and in Patients with Prior CAR T-Cell Therapy: Updated Results from a Phase Ib/II Study

An EZH2 Gene Expression Signature Is Predictive of Differential Efficacy of Chemotherapy Irrespective of EZH2 Mutation Status in Patients with Follicular Lymphoma Treated within the Gallium Trial

Suchergebnisse filtern